BAUSCH & LOMB PHARMA
La probabilité de faillite calculée de BAUSCH & LOMB PHARMA sur 12 mois est de 0,9% (faible). L'entreprise est active depuis 1989 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement. Aucun chiffre de comptes annuels traité n'est disponible ; cette conclusion repose uniquement sur les données du registre et du Moniteur belge.
| Active | 36 ans |
| Direction | 3 |
| Sites | 2 |
| Publications | 19 |
Estimation statistique fondée sur des sources publiques, pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
| Exercice | Type | Dépôt | Référence |
|---|---|---|---|
| 31-12-2024 | volledig | 16-07-2025 | 2025-00304938 |
| 31-12-2023 | volledig | 10-07-2024 | 2024-00237077 |
| 31-12-2022 | volledig | 07-07-2023 | 2023-00233574 |
| 31-12-2021 | volledig | 26-07-2022 | 2022-20267665 |
| 31-12-2020 | volledig | 31-08-2021 | 2021-65900012 |
| 31-12-2019 | volledig | 28-09-2020 | 2020-57400076 |
| 31-12-2018 | volledig | 19-06-2019 | 2019-21600546 |
| 31-12-2017 | volledig | 06-12-2018 | 2018-74300518 |
| 31-12-2016 | volledig | 18-12-2017 | 2017-72500117 |
| 31-12-2015 | volledig | 27-10-2016 | 2016-67000059 |
-
PANDA Manoj KumarAdministrateurActe Moniteur 22363823 (07-10-2022)Actif07-10-2022 → auj.
-
Eberhard KuehneAdministrateurActe Moniteur 24108563 (18-07-2024)Actif30-03-2018 → auj.
2 événements
- 18-07-2024 Nommé· Administrateur
- 30-03-2018 Nommé· Administrateur
-
Pierre GuibourgAdministrateurActe Moniteur 22111695 (20-09-2022)Actif12-12-2016 → auj.
2 événements
- 20-09-2022 Nommé· Administrateur
- 12-12-2016 Nommé· Administrator
Historique, non confirmé récemment (2)
-
William Norman WoodfieldAdministrateurActe Moniteur 18086883 (05-06-2018)Non confirmé récemmentdernière confirmation dans un acte de 2018
-
PricewaterhouseCoopers Reviseurs d'Entreprises SC SCRLPersonne moraleAuditorActe Moniteur 16169260 (12-12-2016)Non confirmé récemmentdernière confirmation dans un acte de 2016
Representants permanents (1)
-
Loris GuidiReprésentant permanent du commissaireActe Moniteur 25103660 (14-08-2025)Representant permanent14-08-2025 → auj.
Anciens dirigeants (4)
-
WOODFIELD WilliamAdministrateurActe Moniteur 22363823 (07-10-2022)Ancien- → 07-10-2022
-
Linda Ann LaGorgaAdministrateurActe Moniteur 18086883 (05-06-2018)Ancien- → 05-06-2018
-
Marcin JedrzejukAdministrateurActe Moniteur 18054485 (30-03-2018)Ancien- → 30-03-2018
-
Ling ZengAdministrateurActe Moniteur 17175995 (15-12-2017)Ancien- → 15-12-2017
| Commissaire / réviseur | Numéro IRE/IBR | Période |
|---|---|---|
| PwC Reviseurs d'EntreprisesActif Commissaire |
- | 14-08-2025 → auj. |
Afficher 2 commissaires précédents
| Loris Guidì Commissaire remplacé par PwC Reviseurs d'Entreprises en 2025 |
- | 20-09-2022 → 14-08-2025 |
| PricewaterhouseCoopers Reviseurs d'Entreprises SCRL Commissaire remplacé par Loris Guidì en 2022 |
- | 19-07-2019 → 20-09-2022 |
| NACE primaire | Commerce de gros de produits pharmaceutiques et médicaux(46460) |
| Forme juridique | SA(014) |
| Date de constitution | 19-12-1989 |
| Status | Actif |
| Code postal | 1150 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active, pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 41342B0932/00D000 | Flandre | 1,7 ha | 1 · 1 485 m² | 5,7 m |
| 25112M0807/00K002 | Wallonie | 540 m² | 1 · 149 m² | 17,4 m · 5 ét. |
| 21683D0358/00V056 | Bruxelles | 205 m² | 1 · 75 m² | 12,3 m · 3 ét. |
Une seule chronologie de tout ce qui est arrivé à cette entreprise, publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
Nous connaissons 27 actes du Moniteur belge pour cette entreprise. Aucun n'a encore été lu : ce qui s'y trouve n'a ici été ni constaté ni réfuté.
14-08-2025 2 administrateurs nommés
- PwC Reviseurs d'Entreprises, Commissaire
- Loris Guidi, Représentant permanent du commissaire
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "PwC Reviseurs d\u0027Entreprises",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent du commissaire",
"person": {
"rrn": null,
"name": "Loris Guidi",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}18-07-2024 Eberhard Kuehne nommé administrateur
- Eberhard Kuehne, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Eberhard Kuehne",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Pausch \u0026 Lomb Pharma"
}
}07-10-2022 Modification des statuts
Détails techniques
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": true
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "BAUSCH \u0026 LOMB PHARMA"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}20-09-2022 2 administrateurs nommés
- Loris Guidì, Commissaire
- Pierre Guibourg, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Loris Guid\u00EC",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Pierre Guibourg",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "BAUSCH \u0026 LOMB PHARMA"
}
}11-03-2020 Changement au sein de l'organe d'administration
Détails techniques
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}27-08-2019 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": "completed",
"notary": {
"name": "Peter VAN MELKEBEKE",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": null,
"filing_date": "2019-06-17",
"act_kind_objet": "OPERATION ASSIMILEE A UNE FUSION PAR ABSORPTION DE \u0022BAUSCH \u0026"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2019-07-31",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb Pharma",
"role": "acquiring",
"address": "1030 Schaerbeek, Boulevard Lambermont 430",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb",
"role": "absorbed",
"address": "1030 Schaerbeek, Boulevard Lambermont 430",
"is_foreign": false,
"legal_form": "SPRL",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"719"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": "2019-01-01",
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "Le patrimoine entier de la soci\u00E9t\u00E9 absorb\u00E9e, sans exception ni r\u00E9serve, est transf\u00E9r\u00E9 \u00E0 titre universel \u00E0 la soci\u00E9t\u00E9 absorbante.",
"equity_transferred_eur": null,
"accounting_effective_date": "2019-01-01"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": "0439.621.618",
"org_name": "NautaDutilh SPRL",
"person_name": null,
"org_rep_person_name": "Louise-Anne Bertin"
},
"summary_narrative": "Le 31 juillet 2019, l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de la soci\u00E9t\u00E9 anonyme Bausch \u0026 Lomb Pharma, si\u00E9geant \u00E0 Schaerbeek, a approuv\u00E9 une op\u00E9ration assimil\u00E9e \u00E0 une fusion par absorption, par laquelle Bausch \u0026 Lomb Pharma absorbe la soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e Bausch \u0026 Lomb, \u00E9galement situ\u00E9e \u00E0 Schaerbeek. Le transfert porte sur l\u0027ensemble du patrimoine de la soci\u00E9t\u00E9 absorb\u00E9e \u00E0 titre universel, avec effet comptable \u00E0 partir du 1er janvier 2019.",
"co_filed_documents": [
"une exp\u00E9dition du proc\u00E8s-verbal",
"deux procurations"
],
"detected_real_type": "fusion_completed",
"referenced_correction": null,
"should_reroute_to_category": null
}19-07-2019 1 administrateur nommé, 1 démissionnaire
- PricewaterhouseCoopers Reviseurs d'Entreprises SCRL, Commissaire
- PricewaterhouseCoopers Reviseurs d'Entreprises SCRL, Commissaire
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "commissaire",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Reviseurs d\u0027Entreprises SCRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Reviseurs d\u0027Entreprises SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "BAUSCH \u0026 LOMB PHARMA"
}
}27-06-2019 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": "proposal",
"notary": {
"name": "Julie Salteur, Louise-Anne Bertin",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2019-06-27",
"filing_date": "2019-06-18",
"act_kind_objet": "D\u00E9p\u00F4t d\u0027un projet commun de fusion par absorption simplifi\u00E9e"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2019-06-17",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb Pharma SA",
"role": "acquiring",
"address": "Boulevard Lambermont 430, 1030 Schaerbeek",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": "0461.095.240",
"name": "Bausch \u0026 Lomb SPRL",
"role": "absorbed",
"address": "Boulevard Lambermont 430, 1030 Bruxelles",
"is_foreign": false,
"legal_form": "SPRL",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"676, 1\u00B0",
"719",
"720 \u00A72"
],
"is_cross_border": false,
"is_silent_merger": true,
"balance_basis_date": "2018-12-31",
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "L\u0027ensemble du patrimoine, tant actif que passif, de Bausch \u0026 Lomb SPRL est transf\u00E9r\u00E9 \u00E0 Bausch \u0026 Lomb Pharma SA par dissolution sans liquidation.",
"equity_transferred_eur": null,
"accounting_effective_date": "2019-01-01"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": "0461.095.240",
"org_name": "NautaDutilh",
"person_name": null,
"org_rep_person_name": "Louise-Anne Bertin"
},
"summary_narrative": "Les soci\u00E9t\u00E9s Bausch \u0026 Lomb Pharma SA et Bausch \u0026 Lomb SPRL, toutes deux \u00E9tablies \u00E0 Bruxelles, ont conjointement r\u00E9dig\u00E9 un projet commun de fusion par absorption simplifi\u00E9e, conform\u00E9ment aux articles 676, 1\u00B0 et 719 du Code des soci\u00E9t\u00E9s. L\u0027op\u00E9ration pr\u00E9voit la transmission int\u00E9grale du patrimoine de Bausch \u0026 Lomb SPRL \u00E0 Bausch \u0026 Lomb Pharma SA, sans liquidation de la soci\u00E9t\u00E9 absorb\u00E9e, avec effet r\u00E9troactif au 1er janvier 2019. Le projet a \u00E9t\u00E9 d\u00E9pos\u00E9 au greffe du tribunal de commerce de Bruxelles le 18 juin 2019 et publi\u00E9 aux Annexes du Moniteur belge le 27 juin 2019.",
"co_filed_documents": [
"le-projet-commun-de-fusion-par-absorption-simplifi\u00E9e-sign\u00E9-le-17-juin-2019"
],
"detected_real_type": "fusion_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}29-06-2018 Opération sur le capital ou les actions
Détails techniques
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}29-06-2018 Opération sur le capital ou les actions
Détails techniques
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}21-06-2018 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": null,
"notary": {
"name": "Nathalie Van Landuyt",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2018-06-21",
"filing_date": "2018-06-12",
"act_kind_objet": "Publication conform\u00E9ment \u00E0 l\u0027article 556 C. Soc."
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2018-05-15",
"unanimous": true
},
"conversion": null,
"detected_kind": "substantive_delegation",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb Pharma",
"role": "other",
"address": "boulevard Lambermont 430 - 1030 Bruxelles",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "Thibaut Willems",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "Nathalie Van Landuyt",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "NautaDutilh",
"role": "other",
"address": "1000 Bruxelles, Chauss\u00E9e de La Hulpe 120",
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"556 C. Soc."
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "Le mandat concerne les formalit\u00E9s de d\u00E9p\u00F4t et de publication du proc\u00E8s-verbal, sans transfert de patrimoine.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Nathalie Van Landuyt",
"org_rep_person_name": null
},
"summary_narrative": "Les actionnaires de Bausch \u0026 Lomb Pharma ont d\u00E9cid\u00E9 \u00E0 l\u0027unanimit\u00E9, par \u00E9crit, le 15 mai 2018, de nommer Thibaut Willems, Nathalie Van Landuyt et/ou tout avocat du cabinet NautaDutilh, si\u00E9geant \u00E0 Bruxelles, en tant que mandataires sp\u00E9ciaux de la soci\u00E9t\u00E9. Ces mandataires ont pour mission d\u0027accomplir toutes les formalit\u00E9s n\u00E9cessaires au d\u00E9p\u00F4t du pr\u00E9sent proc\u00E8s-verbal au greffe du tribunal de commerce de Bruxelles et \u00E0 sa publication au Moniteur belge, conform\u00E9ment \u00E0 l\u0027article 556 du Code des soci\u00E9t\u00E9s.",
"co_filed_documents": [],
"detected_real_type": "substantive_delegation",
"referenced_correction": null,
"should_reroute_to_category": null
}05-06-2018 1 administrateur nommé, 1 démissionnaire
- William Norman Woodfield, Bestuurder
- Linda Ann LaGorga, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Linda Ann LaGorga",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "William Norman Woodfield",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}03-05-2018 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": null,
"notary": {
"name": "Nathalie Van Landuyt",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": null,
"filing_date": null,
"act_kind_objet": "Publication conform\u00E9ment \u00E0 l\u0027article 556 C. Soc."
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"act_date": "2018-03-01",
"unanimous": true
},
"conversion": null,
"detected_kind": "substantive_delegation",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb Pharma SA",
"role": "other",
"address": "boulevard Lambermont, 430 - 1030 Bruxelles",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "Fr\u00E9d\u00E9ric Heremans",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Pierre De Pauw",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Silke Volckaert",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Nathalie Van Landuyt",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "NautaDutilh",
"role": "other",
"address": "1000 Bruxelles, Chauss\u00E9e de La Hulpe 120",
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"556"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "Le mandat concerne l\u0027accomplissement de toutes les formalit\u00E9s n\u00E9cessaires au d\u00E9p\u00F4t du pr\u00E9sent proc\u00E8s-verbal au greffe du Tribunal de Commerce et \u00E0 sa publication au Moniteur belge, ainsi que l\u0027approbation et la signature de tout acte ou document relatif \u00E0 ces formalit\u00E9s.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Nathalie Van Landuyt",
"org_rep_person_name": null
},
"summary_narrative": "Les actionnaires de Bausch \u0026 Lomb Pharma SA ont d\u00E9cid\u00E9 \u00E0 l\u0027unanimit\u00E9, par \u00E9crit, le 1er mars 2018, de d\u00E9signer comme mandataires sp\u00E9ciaux Fr\u00E9d\u00E9ric Heremans, Pierre De Pauw, Silke Volckaert, Nathalie Van Landuyt et/ou tout avocat du cabinet NautaDutilh, pour agir au nom et pour le compte de la soci\u00E9t\u00E9 aux fins de remplir toutes les formalit\u00E9s n\u00E9cessaires au d\u00E9p\u00F4t du pr\u00E9sent acte au greffe du Tribunal de Commerce et \u00E0 sa publication au Moniteur belge, conform\u00E9ment \u00E0 l\u0027article 556 du Code des soci\u00E9t\u00E9s.",
"co_filed_documents": [],
"detected_real_type": "substantive_delegation",
"referenced_correction": null,
"should_reroute_to_category": null
}30-03-2018 1 administrateur nommé, 1 démissionnaire
- Eberhard Kuehne, Bestuurder
- Marcin Jedrzejuk, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marcin Jedrzejuk",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Eberhard Kuehne",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}15-12-2017 Ling Zeng démissionne de son mandat d'administrateur
- Ling Zeng, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Ling Zeng",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}08-08-2017 Opération sur le capital ou les actions
Détails techniques
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma"
}
}12-12-2016 2 administrateurs nommés
- PricewaterhouseCoopers Reviseurs d'Entreprises SC SCRL, Auditor
- Pierre Guibourg, Administrator
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Reviseurs d\u0027Entreprises SC SCRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Pierre Guibourg",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "BAUSCH \u0026 LOMB PHARMA"
}
}24-02-2016 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": null,
"notary": {
"name": "Pierre De Pauw",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2016-02-24",
"filing_date": "2016-01-26",
"act_kind_objet": ""
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2016-01-26",
"unanimous": true
},
"conversion": null,
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb Pharma",
"role": "other",
"address": "Boulevard Lambermont 430, 1030 Schaerbeek",
"is_foreign": false,
"legal_form": "soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "Fr\u00E9d\u00E9ric Heremans",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "Pierre De Pauw",
"role": "other",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": null,
"name": "NautaDutilh",
"role": "other",
"address": "1000 Bruxelles, Chauss\u00E9e de La Hulpe 120",
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"556"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "Aucun transfert de patrimoine n\u0027est effectu\u00E9. L\u0027acte concerne uniquement la d\u00E9signation de mandataires sp\u00E9ciaux pour le d\u00E9p\u00F4t et la publication du proc\u00E8s-verbal.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma",
"legal_form": "soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Pierre De Pauw",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale des actionnaires de Bausch \u0026 Lomb Pharma s\u0027est r\u00E9unie le 26 janvier 2016 et a d\u00E9cid\u00E9 \u00E0 l\u0027unanimit\u00E9 de d\u00E9signer Fr\u00E9d\u00E9ric Heremans, Pierre De Pauw et/ou tout avocat du cabinet NautaDutilh comme mandataires sp\u00E9ciaux de la soci\u00E9t\u00E9. Leur mission est d\u0027accomplir toutes les formalit\u00E9s n\u00E9cessaires au d\u00E9p\u00F4t du pr\u00E9sent acte au greffe du tribunal de commerce et \u00E0 sa publication au Moniteur belge, conform\u00E9ment \u00E0 l\u0027article 556 du Code des soci\u00E9t\u00E9s.",
"co_filed_documents": [],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "director_changes"
}12-02-2016 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": null,
"notary": {
"name": "Pierre De Pauw",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2016-02-12",
"filing_date": "2016-01-26",
"act_kind_objet": ""
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2016-01-26",
"unanimous": true
},
"conversion": null,
"detected_kind": "substantive_delegation",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0439.621.618",
"name": "Bausch \u0026 Lomb Pharma",
"role": "other",
"address": "Boulevard Lambermont 430, 1030 Bruxelles",
"is_foreign": false,
"legal_form": "soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"556"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": null,
"real_estate_included": false,
"patrimony_description": "Le transfert concerne les pouvoirs de repr\u00E9sentation et de gestion n\u00E9cessaires au d\u00E9p\u00F4t du proc\u00E8s-verbal au greffe du tribunal de commerce et \u00E0 sa publication au Moniteur belge.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0439.621.618",
"name_full": "Bausch \u0026 Lomb Pharma",
"legal_form": "soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Pierre De Pauw",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale des actionnaires de Bausch \u0026 Lomb Pharma, r\u00E9unie le 26 janvier 2016, a d\u00E9cid\u00E9 \u00E0 l\u0027unanimit\u00E9 de d\u00E9signer Pierre De Pauw, Fr\u00E9d\u00E9ric Heremans et tout avocat du cabinet NautaDutilh \u00E0 Bruxelles comme mandataires sp\u00E9ciaux de la soci\u00E9t\u00E9. Leur mandat, irr\u00E9vocable et valable trois mois, couvre toutes les formalit\u00E9s n\u00E9cessaires au d\u00E9p\u00F4t du proc\u00E8s-verbal au greffe du tribunal de commerce et \u00E0 sa publication au Moniteur belge, conform\u00E9ment \u00E0 l\u0027article 556 du Code des soci\u00E9t\u00E9s.",
"co_filed_documents": [],
"detected_real_type": "substantive_delegation",
"referenced_correction": null,
"should_reroute_to_category": null
}| Dénomination légaleFR | BAUSCH & LOMB PHARMA |